HIV DNA VACCINE REGULATED BY A CAEV-DERIVED PROMOTER

Item request has been placed!

Item request cannot be made.

Processing Request

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Publication Date:
August 16, 2012

معلومة اضافية
- Document Number:
  20120207782
- Appl. No:
  13/185164
- Application Filed:
  July 18, 2011
- نبذة مختصرة :
  The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for use as a vaccine by the disruption of genes encoding reverse transcriptase, integrase, and Vif. The DNA molecule is further rendered safe by at least a partial deletion of the 3′ LTR.
- Inventors:
  Narayan, Opendra (Lenexa, KS, US); Narayan, Euan (Lenexa, KS, US); Chebloune, Yahia (Grenoble, FR)
- Assignees:
  University of Kansas Medical Center (Kansas City, KS, US), National Institute for Agriculture Research (Paris Cedex 07, FR)
- Claim:
  1. A DNA composition capable of stimulating an immune response comprising: a promoter sequence derived from Caprine Arthritis Encephalitis Goat Lentivirus (CAEV) operably linked to a coding sequence, wherein the coding sequence encodes a gag gene of Human Immunodeficiency Virus (HIV), a pro gene of HIV, a vpx gene of Simian Immunodeficiency Virus (SIV), a vpr gene of SIV, a vpu gene of HIV, a nef gene of HIV, a tat gene of HIV, an env gene of HIV, and a rev gene of HIV, with the coding sequence operably linked to a polyadenylation sequence, and wherein the DNA composition does not include functional reverse transcriptase (rt), integrase (int), and viral infectivity factor (vif) genes.
- Claim:
  2. The DNA composition of claim 1, wherein the coding sequence encodes at least one non-functional gene.
- Claim:
  3. The DNA composition of claim 1, wherein the polyadenylation sequence is an SV40 polyadenylation sequence.
- Claim:
  4. The DNA composition of claim 1, wherein the DNA composition is in a pharmaceutically acceptable carrier.
- Claim:
  5. A pharmaceutical composition comprising: (a) a DNA composition having a promoter sequence derived from Caprine Arthritis Encephalitis Goat Lentivirus (CAEV) operably linked to a coding sequence, wherein the coding sequence encodes a gag gene of Human Immunodeficiency Virus (HIV), a pro gene of HIV, a vpx gene of Simian Immunodeficiency Virus (SIV), a vpr gene of SIV, a vpu gene of HIV, a nef gene of HIV, a tat gene of HIV, an env gene of HIV, and a rev gene of HIV, with the coding sequence operably linked to a polyadenylation sequence, and wherein the DNA composition does not include functional reverse transcriptase (rt), integrase (int), and viral infectivity factor (vif) genes; and, (b) a pharmaceutically acceptable carrier.
- Claim:
  6. The pharmaceutical composition of claim 5, wherein the coding sequence encodes at least one non-functional gene.
- Claim:
  7. The pharmaceutical composition of claim 5, wherein the promoter sequence is a 5′ long terminal repeat (LTR) of SIV.
- Claim:
  8. The pharmaceutical composition of claim 5, wherein the DNA composition lacks a functional 3′ LTR sequence.
- Claim:
  9. The pharmaceutical composition of claim 5, wherein the polyadenylation sequence is an SV40 polyadenylation sequence.
- Claim:
  10. A method of stimulating an immune response in a recipient against Human Immunodeficiency Virus (HIV) comprising: administering to the recipient a DNA composition comprising a promoter sequence derived from Caprine Arthritis Encephalitis Goat Lentivirus (CAEV) operably linked to a coding sequence, wherein the coding sequence encodes a gag gene of Human Immunodeficiency Virus (HIV), a pro gene of HIV, a vpx gene of Simian Immunodeficiency Virus (SIV), a vpr gene of SIV, a vpu gene of HIV, a nef gene of HIV, a tat gene of HIV, an env gene of HIV, and a rev gene of HIV, with the coding sequence operably linked to a polyadenylation sequence, and wherein the DNA composition does not include functional reverse transcriptase (rt), integrase (int), and viral infectivity factor (vif) genes.
- Claim:
  11. The method of claim 10, wherein the coding sequence encodes at least one non-functional gene.
- Claim:
  12. The method of claim 10, wherein the promoter sequence is a 5′ long terminal repeat (LTR) of SIV.
- Claim:
  13. The method of claim 10, wherein the polyadenylation sequence is an SV40 polyadenylation sequence.
- Claim:
  14. The method of claim 10, wherein the DNA composition is in a pharmaceutically acceptable carrier.
- Claim:
  15. The method of claim 10 further comprising administering to the recipient at least one cytokine.
- Claim:
  16. The method of claim 10, further comprising administering to the recipient at least one anti-viral drug therapy.
- Claim:
  17. A method of treating an HIV positive recipient comprising: administering to the recipient a DNA composition comprising a promoter sequence derived from Caprine Arthritis Encephalitis Goat Lentivirus (CAEV) operably linked to a coding sequence, wherein the coding sequence encodes a gag gene of Human Immunodeficiency Virus (HIV), a pro gene of HIV, a vpx gene of Simian Immunodeficiency Virus (SIV), a vpr gene of SIV, a vpu gene of HIV, a nef gene of HIV, a tat gene of HIV, an env gene of HIV, and a rev gene of HIV, with the coding sequence operably linked to a polyadenylation sequence, and wherein the DNA composition does not include functional reverse transcriptase (rt), integrase (int), and viral infectivity factor (vif) genes.
- Claim:
  18. The method of claim 17, wherein the coding sequence encodes at least one non-functional gene.
- Claim:
  19. The method of claim 17, wherein the promoter sequence is a 5′ long terminal repeat (LTR) of SIV.
- Claim:
  20. The method of claim 17, wherein the polyadenylation sequence is an SV40 polyadenylation sequence.
- Claim:
  21. The method of claim 17, wherein the DNA composition is in a pharmaceutically acceptable carrier.
- Claim:
  22. The method of claim 17 further comprising administering to the recipient at least one cytokine.
- Claim:
  23. The method of claim 17, further comprising administering to the recipient at least one anti-viral drug therapy.
- Claim:
  24. A method of vaccinating a recipient against HIV comprising: administering to the recipient a DNA composition comprising a promoter sequence derived from Caprine Arthritis Encephalitis Goat Lentivirus (CAEV) operably linked to a coding sequence, wherein the coding sequence encodes a gag gene of Human Immunodeficiency Virus (HIV), a pro gene of HIV, a vpx gene of Simian Immunodeficiency Virus (SIV), a vpr gene of SIV, a vpu gene of HIV, a nef gene of HIV, a tat gene of HIV, an env gene of HIV, and a rev gene of HIV, with the coding sequence operably linked to a polyadenylation sequence, and wherein the DNA composition does not include functional reverse transcriptase (rt), integrase (int), and viral infectivity factor (vif) genes.
- Claim:
  25. The method of claim 24, wherein the coding sequence encodes at least one non-functional gene.
- Claim:
  26. The method of claim 24, wherein the promoter sequence is a 5′ long terminal repeat (LTR) of SIV.
- Claim:
  27. The method of claim 24, wherein the polyadenylation sequence is an SV40 polyadenylation sequence.
- Claim:
  28. The method of claim 24, wherein the DNA composition is in a pharmaceutically acceptable carrier.
- Claim:
  29. The method of claim 24 further comprising administering to the recipient at least one cytokine.
- Claim:
  30. The method of claim 24 further comprising administering to the recipient at least one anti-viral drug therapy.
- Current U.S. Class:
  4242/021
- Current International Class:
  61; 61; 12
- الرقم المعرف:
  edspap.20120207782

تعليقات

No Comments.